Joaquin Seras Franzoso I am researcher and PI at the Drug Delivery & Targeting Group belonging to the "Advanced Therapies and Advanced Interventions, Nanomedicine, Transplant & Donation - AVANT " eCORE at Vall d'Hebron Institute of Research (VHIR). I combine this main activity with acting as associate lecturer at the Autonomous University of Barcelona (UAB). Institutions of which they are part Main researcher Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT) Vall Hebron Institut de Recerca LinkedIn Twitter Orcid Email Joaquin Seras Franzoso LinkedIn Twitter Orcid Email Institutions of which they are part Main researcher Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT) Vall Hebron Institut de Recerca I am researcher and PI at the Drug Delivery & Targeting Group belonging to the "Advanced Therapies and Advanced Interventions, Nanomedicine, Transplant & Donation - AVANT " eCORE at Vall d'Hebron Institute of Research (VHIR). I combine this main activity with acting as associate lecturer at the Autonomous University of Barcelona (UAB).
I performed my PhD at the Autonomous University of Barcelona (UAB, 2012). There, I focused on the development of first-in-class biomedical uses for bacterial Inclusion Bodies (IBs). IBs are recombinant protein deposits, between the nano- and micro scale, historically discarded as waste by products of protein production. My research studied the IB-exerted stimuli on mammalian cell interfaces when producing complex nanotopographies for tissue engineering. After my PhD I devoted myself to expand the catalogue of biomedical uses for IBs, as high added value biomaterials. I engineered IBs to be used as depots for the slow release of therapeutic proteins, polyvalent coatings and immunomodulatory particles. I moved to Vall d'Hebron Research Institute (VHIR) in 2015 awarded with an AECC post-doctoral fellowship. Here, I have continued my work in the nano-sphere. Particularly, I have participated in the development of Polymeric Micelles (PM) for the PM-mediated intracellular delivery of therapeutic antibodies, targeting cancer stem cell intrinsic drug resistance. In parallel, I started to explore the potential of extracellular vesicles (EVs). First, as central mediators of intercellular communication with roles in cancer cell plasticity regulation and premetastatic niche conditioning. Secondly, exploiting EVs capacity as protein delivery systems. In this regard, I focused on the generation of protein therapeutics loaded in vivo into EVs. This approach combines protein production and NP functionalization in a single step with intended applications in rare diseases and cancer therapy. I have participated in >20 competitive projects with an accumulated funding of > 3 Milion euros (PI of two). This activity rendered >50 articles (hi=25) in international journals and >60 contributions to congresses. Complementing this activity I engaged teaching undergraduates (2010-2012 & 2021 - , AQU Lecturer accreditation) at UAB and mentoring master and PhD students.
Projects Nanoclustered Affimers for Targeted KRAS Ablation in Pancreatic Ductal Adenocarcinoma IP: Joaquin Seras Franzoso Collaborators: Diana Fernandes de Rafael Funding agency: Asociación Cáncer de Páncreas Funding: 50000 Reference: ACANPAN/PROJECTES/2023/SERAS Duration: 05/12/2023 - 04/12/2025 Bioquímica Clínica, Vehiculització de Fàrmacs i Teràpia (Clinical Biochemistry, Drug Delivery & Therapy, CB-DDT) IP: - Collaborators: José Antonio Arranz Amo, Raquel Barquin Del Pino, Bioquímica Clínica, Vehiculització de Fàrmacs i Teràpia (Clinical Biochemistry, Drug Delivery & Therapy, CB-DDT), Clara Ramírez Serra, Yolanda Villena Ortiz, Joan López Hellin, Albert Blanco Grau, Roser Ferrer Costa, Joaquin Seras Franzoso, Bioquímica Clínica, Vehiculització de Fàrmacs i Teràpia (Clinical Biochemistry, Drug Delivery & Therapy, CB-DDT), Laura Castillo Ribelles, Clara Carnicer Cáceres, Marina Giralt Arnaiz, Ana Gomez Garcia, Simon Schwartz Navarro, Pablo Gabriel Medina, Bioquímica Clínica, Vehiculització de Fàrmacs i Teràpia (Clinical Biochemistry, Drug Delivery & Therapy, CB-DDT), Bioquímica Clínica, Vehiculització de Fàrmacs i Teràpia (Clinical Biochemistry, Drug Delivery & Therapy, CB-DDT), Laura Castellote Bellés, Daniel Bravo Nieto, Luz María Cruz Carlos, Clara Sanz Gea, Alba Estela García Fernández, Maria del Pilar Reimundo Diaz-Fierros, Belen Garcia Prats, Bioquímica Clínica, Vehiculització de Fàrmacs i Teràpia (Clinical Biochemistry, Drug Delivery & Therapy, CB-DDT), JAUME VIMA BOFARULL, Bioquímica Clínica, Vehiculització de Fàrmacs i Teràpia (Clinical Biochemistry, Drug Delivery & Therapy, CB-DDT), Diana Fernandes de Rafael, Maria Francesca Cortese , Sandra Mancilla Zamora Funding agency: Agència Gestió Ajuts Universitaris i de Recerca Funding: 60000 Reference: 2021 SGR 01173 Duration: 01/01/2022 - 30/06/2025 Impacto y valor pronóstico de vesículas extracelulares tumorales provenientes de células madre cancerígenas en tumores de mama triple negativo. IP: Joaquin Seras Franzoso Collaborators: Laura García Latorre, Impacto y valor pronóstico de vesículas extracelulares tumorales provenientes de células madre cancerígenas en tumores de mama t, Esther Zamora Adelantado, Sandra Mancilla Zamora, Zamira Vanessa Diaz Riascos, Belen Garcia Prats Funding agency: Instituto de Salud Carlos III Funding: 99220 Reference: PI22/01301 Duration: 01/01/2023 - 31/12/2026 MIMIC-KeY - A KEY TO THE RATIONAL DESIGN OF EXTRACELLULAR VESICLES-MIMICKING NANOPARTICLES. IP: Simon Schwartz Navarro Collaborators: Joaquin Seras Franzoso, Julia German Cortes, Zamira Vanessa Diaz Riascos Funding agency: EUROPEAN COMMISSION Funding: 457250 Reference: MIMIC-KEY_H2020-FETPROACT-2020 Duration: 01/06/2021 - 30/11/2025 Pagination First page « Previous page ‹ Page 1 Current page 2 Page 3 Page 4 Next page › Last page »
